journal article·2020-07-27Open access

Contact Lenses as Drug Delivery System for Glaucoma: A Review

Assumpta Peral, Alejandro Martinez-Aguila, Cristina Pastrana, Fernando Huete-Toral, Carlos Carpena-Torres, Gonzalo Carracedo

Applied Sciences· Volume 10· Issue 15

Abstract

Glaucoma is an optical neuropathy associated to a progressive degeneration of retinal ganglion cells with visual field loss and is the main cause of irreversible blindness in the world. The treatment has the aim to reduce intraocular pressure. The first therapy option is to instill drugs on the ocular surface. The main limitation of this is the reduced time of the drug staying on the cornea. This means that high doses are required to ensure its therapeutic effect. A drug-loaded contact lens can diffuse into the post lens tear film in a constant and prolonged flow, resulting in an increased retention of the drug on the surface of the cornea for up to 30 min and thus providing a higher drug bioavailability, increasing the therapeutic efficacy, reducing the amount of administered drug, and thereby provoking fewer adverse events. Several different systems of drug delivery have been studied in recent decades; ranging from more simple methods of impregnating the lenses, such as soaking, to more complex ones, such as molecular imprinting have been proposed. Moreover, different drugs, from those already commercially available to new substances such as melatonin have been studied to improve the glaucoma treatment efficacy. This review describes the role of contact lenses as an innovative drug delivery system to treat glaucoma.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ocular Surface and Contact Lens · Glaucoma and retinal disorders · Proteoglycans and glycosaminoglycans research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Optometry and Vision, Faculty of Optic and Optometry, Universidad Complutense de Madrid, 28037 Madrid, Spain

Ocupharm Group Research, Universidad Complutense de Madrid, 28037 Madrid, Spain

Department of Biochemistry and Molecular Biology, Faculty of Optic and Optometry, Universidad Complutense de Madrid, 28037 Madrid, Spain

Funding

Instituto de Salud Carlos III

References (100+)

Show source-provided references
1. Ocular perfusion pressure and ocular blood flow in glaucoma10.1016/j.coph.2012.09.003 ↗
2. Primary open-angle glaucoma10.1016/S0140-6736(04)16257-0 ↗
3. Risk factors for glaucoma onset and progression10.1016/j.survophthal.2008.08.006 ↗
4. Under pressure: Cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy10.1146/annurev.neuro.051508.135728 ↗
5. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma10.1001/archopht.120.6.701 ↗
6. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial10.1001/archopht.120.10.1268 ↗
7. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups10.1016/S0002-9394(01)01028-5 ↗
8. Vass, C., Hirn, C., Sycha, T., Findl, O., Bauer, P., and Schmetterer, L. (2007). Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst. Rev., 2007.10.1002/14651858.CD003167.pub3 ↗
9. The number of people with glaucoma worldwide in 2010 and 202010.1136/bjo.2005.081224 ↗
10. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis10.1016/j.ophtha.2014.05.013 ↗
11. Managing glaucoma in developing countries10.1590/S0004-27492011000200001 ↗
12. Temba glaucoma study: A population-based cross-sectional survey in urban South Africa10.1016/S0161-6420(02)01568-3 ↗
13. Proteome analysis of human aqueous humor10.1167/iovs.10-5531 ↗
14. Pathophysiology of hydrodynamics in glaucoma
15. Aqueous humor dynamics: A review10.2174/1874364101004010052 ↗
16. A boussinesq model of natural convection in the human eye and the formation of Krukenberg’s spindle10.1114/1.1477447 ↗
17. The trabecular meshwork outflow pathways: Structural and functional aspects10.1016/j.exer.2009.02.007 ↗
18. Uveoscleral outflow—A review10.1016/j.exer.2008.12.012 ↗
19. Identification of lymphatics in the ciliary body of the human eye: A novel “uveolymphatic” outflow pathway10.1016/j.exer.2009.08.010 ↗
20. Biomechanics of the optic nerve head10.1016/j.exer.2009.02.003 ↗
21. Correlation of retinal nerve fiber layer thickness and visual fields in glaucoma: A broken stick model10.1016/j.ajo.2014.01.014 ↗
22. Screening performance of functional and structural measurements of neural damage in open-angle glaucoma: A case-control study from the Baltimore Eye Survey10.1097/00061198-200010000-00002 ↗
23. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: The Los Angeles Latino Eye Study10.1016/j.ophtha.2004.01.025 ↗
24. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey10.1001/jama.1991.03470030069026 ↗
25. The African Caribbean Eye Survey: Risk factors for glaucoma in a sample of African Caribbean people living in London10.1038/eye.1994.64 ↗
26. The pathophysiology and treatment of glaucoma: A review10.1001/jama.2014.3192 ↗
27. Biometry and primary angle-closure glaucoma among Chinese, white, and black populations10.1016/S0161-6420(97)30112-2 ↗
28. Prediction of functional loss in glaucoma from progressive optic disc damage10.1001/archophthalmol.2009.276 ↗
29. Comparison of retinal nerve fiber layer and optic disc imaging for diagnosing glaucoma in patients suspected of having the disease10.1016/j.ophtha.2007.11.008 ↗
30. Comparison of the GDx VCC scanning laser polarimeter, HRT II confocal scanning laser ophthalmoscope, and stratus OCT optical coherence tomograph for the detection of glaucoma10.1001/archopht.122.6.827 ↗
31. Enhanced detection of open-angle glaucoma with an anatomically accurate optical coherence tomography-derived neuroretinal rim parameter10.1016/j.ophtha.2012.09.055 ↗
32. Estimating the rate of retinal ganglion cell loss in glaucoma10.1016/j.ajo.2012.04.022 ↗
33. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications10.1016/S0039-6257(02)00295-3 ↗
34. Topical beta blockers in asthmatic patients-is it safe?10.1080/02713680902989337 ↗
35. Adreno-melatonin receptor complexes control ion homeostasis and intraocular pressure—Their disruption contributes to hypertensive glaucoma10.1111/bph.14971 ↗
36. Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice10.1124/jpet.115.231456 ↗
37. Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits10.1124/jpet.110.178319 ↗
38. The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analogue, 5-MCA-NAT, in rabbit eyes10.1167/iovs.10-6099 ↗
39. Circadian rhythm in intraocular pressure: A rabbit model10.3109/02713688109001822 ↗
40. The role of melatonin in glaucoma: Implications concerning pathophysiological relevance and therapeutic potential10.1111/j.1600-079X.2010.00816.x ↗
41. Requirement of intact sympathetic transmission for the ocular hypotensive effects of melatonin and 5-MCA-NAT10.1016/j.autneu.2007.07.004 ↗
42. Melatonin analogue agomelatine reduces rabbit’s intraocular pressure in normotensive and hypertensive conditions10.1016/j.ejphar.2012.12.009 ↗
43. Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients10.1111/opo.12189 ↗
44. New treatments for ocular hypertension10.1016/j.autneu.2008.12.009 ↗
45. Presence of diadenosine polyphosphates in the aqueous humor: Their effect on intraocular pressure10.1124/jpet.102.041368 ↗
46. Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma10.1007/s11302-016-9547-y ↗
47. Preservatives in eyedrops: The good, the bad and the ugly10.1016/j.preteyeres.2010.03.001 ↗
48. Sustained drug delivery in glaucoma10.1097/ICU.0000000000000031 ↗
49. Extended drug delivery by contact lenses for glaucoma therapy10.1016/j.jconrel.2012.06.017 ↗
50. Ocular drug delivery10.1208/s12248-010-9183-3 ↗
51. Topical and systemic drug delivery to the posterior segments10.1016/j.addr.2005.09.004 ↗
52. Intraocular penetration of antimicrobial agents in ophthalmic infections and drug delivery strategies10.1517/17425240902798119 ↗
53. Recent advances in ophthalmic drug delivery10.4155/tde.10.40 ↗
54. Risk factors for noncompliance with glaucoma follow-up visits in a residents’ eye clinic10.1016/S0161-6420(98)91134-4 ↗
55. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study10.1016/j.ophtha.2008.09.004 ↗
56. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: Advantages in clinical practice10.1517/14656566.2014.936850 ↗
57. Ocular surface disease and quality of life in patients with glaucoma10.1016/j.ajo.2011.05.033 ↗
58. Dry Eye Treatment Based on Contact Lens Drug Delivery: A Review10.1097/ICL.0000000000000184 ↗
59. Promising therapeutic drug delivery systems for glaucoma: A comprehensive review
60. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month10.1016/j.biomaterials.2013.09.032 ↗
61. Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects10.1001/archopht.1992.01080160106043 ↗
62. Cytotoxicity of ophthalmic preservatives10.1016/0002-9394(74)90016-6 ↗
63. Musgrave, C.S.A., and Fang, F. (2019). Contact Lens Materials: A Materials Science Perspective. Materials, 12.10.3390/ma12020261 ↗
64. A comprehensive review on contact lens for ophthalmic drug delivery10.1016/j.jconrel.2018.05.020 ↗
65. Determinants of the frequency of contact lens wear10.1097/ICL.0b013e31827a7ad3 ↗
66. International survey of rigid contact lens fitting10.1097/OPX.0b013e31827cd8be ↗
67. Mechanical Properties of Contact Lens Materials10.1097/ICL.0000000000000442 ↗
68. Possibility of the application of ophthalmic drugs with the use of gel contact lenses
69. Treatment of acute glaucoma
70. Pilocarpine therapy with soft contact lenses10.1016/0002-9394(72)90062-1 ↗
71. Management of acute glaucoma with pilocarpine-soaked hydrophilic lens10.1136/bjo.58.7.674 ↗
72. Pilocarpine dispensation for the soft hydrophilic contact lens10.1136/bjo.59.8.455 ↗
73. Fluorophotometry in contact lens research: The next step10.1097/00006324-199805000-00020 ↗
74. Ocular drug delivery system: A reference to natural polymers10.1517/17425247.2012.690733 ↗
75. Jones, L., Brennan, N.A., Gonzalez-Meijome, J., Lally, J., Maldonado-Codina, C., Schmidt, T.A., Subbaraman, L., Young, G., Nichols, J.J., and members of the TFOS International Workshop on Contact Lens Discomfort (2013). The TFOS International Workshop on Contact Lens Discomfort: Report of the contact lens materials, design, and care subcommittee. Investig. Ophthalmol. Vis. Sci., 54.10.1167/iovs.13-13215 ↗
76. ElShaer, A., Mustafa, S., Kasar, M., Thapa, S., Ghatora, B., and Alany, R.G. (2016). Nanoparticle-Laden Contact Lens for Controlled Ocular Delivery of Prednisolone: Formulation Optimization Using Statistical Experimental Design. Pharmaceutics, 8.10.3390/pharmaceutics8020014 ↗
77. Clinical factors associated with contact lens dropout10.1016/j.clae.2018.12.002 ↗
78. A review of international medical device regulations: Contact lenses and lens care solutions10.1016/j.clae.2018.11.001 ↗
79. The TFOS International Workshop on Contact Lens Discomfort: Report of the contact lens interactions with the ocular surface and adnexa subcommittee10.1167/iovs.13-13187 ↗
80. Contact Lens-related Complications: A Review
81. Contact Lens Solutions and Contact Lens Discomfort: Examining the Correlations Between Solution Components, Keratitis, and Contact Lens Discomfort10.1097/ICL.0000000000000458 ↗
82. Benzalkonium chloride and glaucoma10.1089/jop.2013.0174 ↗
83. Diquafosol delivery from silicone hydrogel contact lenses: Improved effect on tear secretion10.1089/jop.2016.0193 ↗
84. In vitro and in vivo delivery of the secretagogue diadenosine tetraphosphate from conventional and silicone hydrogel soft contact lenses10.1016/j.optom.2013.07.004 ↗
85. In Vitro Topical Delivery of Chlorhexidine to the Cornea: Enhancement Using Drug-Loaded Contact Lenses and β-Cyclodextrin Complexation, and the Importance of Simulating Tear Irrigation10.1021/acs.molpharmaceut.0c00140 ↗
86. Minami, T., Ishida, W., Kishimoto, T., Nakajima, I., Hino, S., Arai, R., Matsunaga, T., Fukushima, A., and Yamagami, S. (2019). In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses. PLoS ONE, 14.10.1371/journal.pone.0210362 ↗
87. Drug delivery to the posterior segment of the eye through hydrogel contact lenses10.1111/j.1444-0938.2010.00553.x ↗
88. Effect of vitamin-E integration on delivery of prostaglandin analogs from therapeutic lenses10.1016/j.jcis.2018.12.036 ↗
89. In vitro and in vivo evaluation of ketotifen fumarate-loaded silicone hydrogel contact lenses for ocular drug delivery10.3109/10717544.2010.522612 ↗
90. Experimental studies on soft contact lenses for controlled ocular delivery of pirfinedone: In vitro and in vivo10.1080/10717544.2016.1204570 ↗
91. Dual drug delivery from vitamin e loaded contact lenses for glaucoma therapy10.1016/j.ejpb.2015.06.001 ↗
92. Improving the loading and release of NSAIDs from pHEMA hydrogels by copolymerization with functionalized monomers10.1002/jps.20761 ↗
93. Azulene incorporation and release by hydrogel containing methacrylamide propyltrimenthylammonium chloride, and its application to soft contact lens10.1016/S0168-3659(03)00368-7 ↗
94. Application of polymer gels containing side-chain phosphate groups to drug-delivery contact lenses10.1002/app.22080 ↗
95. Development and efficacy of a drug-releasing soft contact lens10.1167/iovs.12-10614 ↗
96. Release characteristics of novel pH-sensitive p(HEMA-DMAEMA) hydrogels containing 3-(trimethoxy-silyl) propyl methacrylate10.1021/bm034048r ↗
97. β-Cyclodextrin hydrogels for the ocular release of antibacterial thiosemicarbazones10.1016/j.carbpol.2012.12.033 ↗
98. Adjusting biomaterial composition to achieve controlled multiple-day release of dexamethasone from an extended-wear silicone hydrogel contact lens10.1080/09205063.2013.840228 ↗
99. Drug loading optimization and extended drug delivery of corticoids from pHEMA based soft contact lenses hydrogels via chemical and microstructural modifications10.1016/j.ijpharm.2015.04.037 ↗
100. A review on therapeutic contact lenses for ocular drug delivery10.3109/10717544.2016.1138342 ↗